Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annu... (tigational regimen whichreplaces doxorub...)

HOME >> MEDICINE >> TECHNOLOGY

Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting

Date:12/11/2007

tigational regimen which replaces doxorubicin with pixantrone, CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, and rituximab) monthly for six cycles. During treatment, patients are evaluated for response to therapy after cycle 4 and at the end of treatment. During follow up disease status is assessed every three months during first year and every six months thereafter.

Cardiac function, as determined by serial multi-gated nuclear scans (MUGA), is evaluated prior to initiation of therapy and then at the completion of every two cycles of therapy. Thus far, routine prophylactic administration of G-CSF was utilized equally across treatment arms in approximately half of study participants. The interim analysis was conducted after at least four cycles of therapy to determine if the dose of pixantrone (150 mg/m2) was adequate to induce major objective responses comparable to the doxorubicin arm as well as to evaluate potential differences in major toxicities. Members of the independent Data Safety Monitoring Board (DSMB) review safety data on a quarterly basis.

Pixantrone in Clinical Studies

There are currently two clinical studies of pixantrone in aggressive NHL patients, RAPID and a phase III single agent trial, known as EXTEND. The EXTEND trial explores the role of single-agent treatment as a salvage regimen in patients with relapsed aggressive NHL who have failed at least two prior treatment regimens. Patients are randomized to receive either pixantrone or another single-agent drug of the physician's choice currently used for the treatment of this patient population.

A phase III trial of pixantrone for patients with indolent NHL was launched in September 2007. The trial, PIX303, will examine the complete remission rates and time to disease progression for the combination regimen of fludarabine, pixantrone and rituximab (FP-R) compared to the combination of fludarabine and rituximab (F-R) in the treatment of patients who have r
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership

Post Your Comments:

(Date:2/9/2010)... Feb. 9 Volcano Corporation (Nasdaq: ... of precision intravascular therapy guidance tools designed to ... peripheral vascular disease, announced today that it has ... from Lumen Biomedical. Volcano became the exclusive global ... 2009 . This acquisition reinforces Volcano,s dedication to ...

(Date:2/9/2010)... Glycemion Strategies, Inc., an ... diabetic consumers and their professional healthcare providers, announced ... to benefit the 30,000 US Diabetes Educators and ... serve. ,, The Portrait Health™ ... provide real-time access to health information, especially in ...

(Date:2/9/2010)... SOUTHFIELD, Mich. , Feb. 9 /PRNewswire-FirstCall/ ... TEAM ), a worldwide provider of information technology ... that it has named Guido Roumans as director ... responsible for service delivery, relationship management and ongoing ... customers. ,, Roumans has nearly 20 years of ...

Breaking Medicine Technology:Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 2 Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 3 Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 4 Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter 5 Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators 2 Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators 3 TechTeam Global Appoints Life Sciences Services Director 2 TechTeam Global Appoints Life Sciences Services Director 3 Echo Therapeutics to Present at Jessup 26 Lamont 2009 Growth Stock Conference 52099 1 Echo Therapeutics to Present at Jessup 26 Lamont 2009 Growth Stock Conference 52099 2 Regado Biosciences Expands Medical Advisory Board 13085 1 Regado Biosciences Expands Medical Advisory Board 13085 2 Regado Biosciences Expands Medical Advisory Board 13085 3 Regado Biosciences Expands Medical Advisory Board 13085 4 Elder Boom Will Be Felt Worldwide 52094 1 Elder Boom Will Be Felt Worldwide 52094 2

[0] Volcano Corporation Completes Acquisition of Lumen Biomedical's Xtract(TM) Thrombus Aspiration Catheter [0] Portrait Health(TM) Emergency Medical Data Retrieval Program-Glycemion Strategies Announces Free Membership for Diabetes Educators [0] TechTeam Global Appoints Life Sciences Services Director

... Oct. 11 KineMed Inc., a,pathway-based drug discovery ... the ability of an investigational agent,to regenerate nerve ... brain involved,with cognition and mood. The agent, part ... performance in a behavioral test in a,preclinical model. ...

... 11 deCODE genetics,(Nasdaq: DCGN ) today announced ... variations in the genome (called SNPs) that the company,has ... The SNPs are located on chromosome 9 and were ... journal Science in July, deCODE,scientists found that people who ...

Other Medicine Technology:KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 2 KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model 3 deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack 2 deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack 3

KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack

(Date:2/9/2010)... for bladder biopsies done in doctor,s office boosted ... (HealthDay News) -- After Medicare sweetened payments for ... York City practice performed many more in-office bladder ... roughly the same, a new study finds. , ... 50 percent after the U.S. Centers for Medicare ...

(Date:2/9/2010)... Feb. 9 The American Council ... and one of the largest fitness certification, education ... key findings from an exclusive study on the ... University of Wisconsin , La Crosse , ... that kettlebells provide a much higher-intensity workout than ...

(Date:2/9/2010)... Feb. 9 Vescent Labs Inc., ... announced today that a new infomercial featuring its revolutionary ... in February. Competitive Edge Media, based in San ... agency for the National TV campaign, and will represent ... Skyler Ditchfield , Vescent Labs Inc. CEO, said, "We,re ...

(Date:2/9/2010)... Movement to Fight Heart Disease in Eastern Washington , ... ... -- Jiffy Lube service centers in Spokane, Kennewick, Richland, Pasco, ... in year three of the Jiffy Lube Maintenance Partners for ... the American Heart Association’s Go Red For Women movement, the ...

(Date:2/9/2010)... City Fitness Philadelphia become the newest distributors for growing national ... ... February 9, 2010 -- Diet-to-Go, a national leader in the ... reach into the Philadelphia area by adding a pair of ... , ,The new locations help extend Diet-to-Go,s reach into the ...

Breaking Medicine News(10 mins):Health News:Medicare Cost-Saving Moves Can Backfire 2 Health News:Medicare Cost-Saving Moves Can Backfire 3 Health News:American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time 2 Health News:American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time 3 Health News:Company Invites Women to STOP PMS - Take the 10-Minute Challenge 2 Health News:Company Invites Women to STOP PMS - Take the 10-Minute Challenge 3 Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 2 Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 3 Health News: Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign 4 Health News:Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health 2 Health News:Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health 3

[0] Medicare Cost-Saving Moves Can Backfire [0] American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time [0] Company Invites Women to STOP PMS - Take the 10-Minute Challenge [0] Eastern Washington Jiffy Lube Service Centers Embark on Year Three of Successful Maintenance Partners For Life Campaign [0] Diet-to-Go Welcomes 2 Key Philadelphia Fitness Centers as Partners-in-Health

... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... Conference on November 11, 2008. The Company will be ... and Christopher,M. Hix, Vice President and Chief Financial Officer., ... CST, at,the Four Seasons Hotel in Chicago, Illinois. It ...

... Serious Lung Disease 4th Leading Cause of Death in ... is supporting,national COPD Awareness Month, to help raise awareness ... COPD Awareness Month, AllerAir will be making downloadable,tips available ... as well,as dedicating their November newsletter and blogs to ...

... TORONTO, Nov. 3 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc.,a ... cancer therapies, announced today that Dr. Alan M.,Ezrin, ... will present a,corporate update at Rodman & Renshaw ... New York City from November 10th - 12th ...

... medicine company,PreMD Inc. (TSX: PMD; PREMF.pk) today announced it ... it is reviewing the eligibility of the,Company,s common shares ... is being reviewed under the TSX,s Remedial Review Process,and ... requirements for continued,listing. If the Company cannot demonstrate that ...

... and new stock ... repurchase program, BOSTON, ... radiology and medical image and information management solutions,today reported unaudited financial ... (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ), Q3 Financial Highlights ...

... more prone to act out than those without deployed kin ... military personnel deployed to Iraq and Afghanistan are more likely ... a new study shows. , Researchers studied 169 families with ... in a day-care center at a Marine base. , Of ...

Robbins & Myers to Present at Baird's 2008 Industrial Conference November 11, 2008 AllerAir Dedicates November to COPD Awareness Month Bradmer to present at Rodman & Renshaw Healthcare Conference Listing Review initiated by the Toronto Stock Exchange AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008 Kids With Parent in War Zone Face Behavior Risks

... Properly manufactured radiation protective eyewear can ... high quality frames and materials offer the ... Our lenses are made of Schott RS-520 ... standards. Most Pulse Glasses are offered with ...

... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...

... and comfortable eye protection Properly manufactured ... of scatter radiation. Our high quality frames ... comfort with minimized weight. Our lenses are ... that meet all industry standards. Most Pulse ...

... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...

Medicine Products:

Vet Economy Wrap Carbon Wrap Metal Standard

Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annu...(tigational regimen whichreplaces doxorub...),Health